查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1609152

新抗原癌症疫苗市场：按产品、技术、递送机制、新抗原类型、给药途径和应用 - 2025-2030 年全球预测

Neoantigen Cancer Vaccine Market by Product, Technology, Delivery Mechanism, Neoantigen Type, Route of Administration, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

新抗原癌症疫苗市场2023年估值为5,714万美元，预计2024年将达6,044万美元，复合年增长率为5.17%，预计2030年将达8,135万美元。

新抗原癌症疫苗是肿瘤学领域快速发展的前沿领域，专注于利用人体免疫系统靶向肿瘤特异性抗原的个人化免疫疗法。这种个人化方法的需求源于癌细胞表现出的独特突变特征，它可以实现传统治疗方法经常错过的高度特异性靶向。新抗原疫苗在早期临床试验、復发性肿瘤和个人化治疗中找到了重要应用，最终用户范围从专门的癌症诊所到从事尖端研究的大型医院网路。基因组技术的进步、生物资讯学能力的扩展以及对肿瘤免疫学的更好理解推动了市场成长，从而推动了针对个体基因谱的有效治疗方案的乐观情绪。

主要市场统计
基准年[2023] 5714万美元
预测年份 [2024] 6044万美元
预测年份 [2030] 8135万美元
复合年增长率（%） 5.17%

然而，这个市场并非没有挑战。个人化疫苗开发的高成本以及新抗原识别和检验的复杂性是主要障碍。监管挑战、漫长的临床试验过程以及对更可靠和更广泛的疗效资料的需求使市场扩张更加复杂。儘管有这些限制，但机会仍然存在，特别是对于那些能够创新高通量定序技术和计算演算法以提高新抗原预测准确性的公司而言。生技公司和学术机构之间合作突破癌症免疫疗法的界限是加速成长的一条有希望的道路。

可以在改善患者分层流程、开发更好的疫苗功效预测模型以及整合机器学习以缩短开发时间等领域激发创新。市场格局不稳定且竞争激烈，其特征是技术快速发展和策略联盟的增加。透过专注于个人化治疗解决方案，公司可以显着脱颖而出。透过投资合作研究，将最尖端科技与现实世界的临床应用相结合，简化监管核准机制，并最大限度地利用从早期资料中获得的见解，有效地追求业务成长。这种方法不仅可以改善治疗效果，还可以增强我们在这变革领域的竞争力。

市场动态：揭示快速发展的新抗原癌症疫苗市场的关键市场洞察

新抗原癌症疫苗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球癌症盛行率上升
    • 改善基因组定序和免疫治疗
    • 倾向于癌症的早期诊断和治疗
  • 市场限制因素
    • 製造高成本且复杂
  • 市场机会
    • 持续研发以提高新抗原癌症疫苗的功效
    • 联合治疗的新进展
  • 市场挑战
    • 副作用和伦理问题

波特五力：驾驭新抗原癌症疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解新抗原癌症疫苗市场的外部影响

外部宏观环境因素在塑造新抗原癌症疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解新抗原癌症疫苗市场的竞争状况

新抗原癌症疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵新抗原癌症疫苗市场供应商的绩效评估

FPNV 定位矩阵是评估新抗原癌症疫苗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划新抗原癌症疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对新抗原癌症疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球癌症发生率正在上升
      • 基因组测序和免疫治疗的进展
      • 癌症早期诊断和治疗的趋势
    • 抑制因素
      • 製造成本高且复杂
    • 机会
      • 持续研发以提高新抗原癌症疫苗的功效
      • 联合治疗的新进展
    • 任务
      • 副作用和伦理问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章新抗原癌症疫苗市场：副产品

  • 现成的新抗原疫苗
  • 个人化新抗原疫苗

第七章新抗原癌症疫苗市场：依技术分类

  • HLA型检测
  • RNA定序
  • 全基因组序列分析

第八章新抗原癌症疫苗市场依输送机制划分

  • 电穿孔
  • 基因枪
  • 脂质体
  • 病毒体

第九章新抗原癌症疫苗市场（以新抗原类型）

  • 树突状细胞
  • 核酸
  • 合成生长链胜肽
  • 癌细胞

第10章新抗原癌症疫苗市场：依给药途径分类

  • 肌肉注射
  • 静脉
  • 经皮的

第十一章新抗原癌症疫苗市场：依应用分类

  • 脑肿瘤
  • 消化道癌症
  • 肺癌
  • 恶性黑色素瘤

第十二章美洲新抗原癌症疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十三章亚太地区新抗原癌症疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十四章欧洲、中东和非洲新抗原癌症疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • "
  • "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • Advaxis Inc.
  • Agenus Inc.
  • AstraZeneca plc
  • Avidea Technologies
  • BioLineRx
  • BioNTech SE
  • Brightpath Biotherapeutics Co., Ltd.
  • CureVac NV
  • Elicio Therapeutics Inc
  • F. Hoffmann-La Roche Ltd.
  • Genocea Biosciences Inc
  • Gilead Sciences, Inc.
  • Gritstone bio, Inc.
  • Immunomic Therapeutics, Inc.
  • IMV Inc
  • ISA Pharmaceuticals BV
  • Medigene AG
  • Merck & Co., Inc.
  • Neophore Limited
  • Nouscom
  • Nykode Therapeutics ASA
  • OSE Immunotherapeutics
  • Takis srl
Product Code: MRR-5C6F41F5AFED

The Neoantigen Cancer Vaccine Market was valued at USD 57.14 million in 2023, expected to reach USD 60.44 million in 2024, and is projected to grow at a CAGR of 5.17%, to USD 81.35 million by 2030.

Neoantigen cancer vaccines represent a burgeoning frontier in oncology, focusing on personalized immunotherapy that harnesses the body's immune system to target tumor-specific antigens. The necessity for such a tailored approach stems from the unique mutational signatures presented by cancer cells, enabling highly specific targeting that traditional therapies often miss. Neoantigen vaccines find significant applications in early-stage trials, recurrent tumors, and personalized treatments, with end-users spanning from specialized oncology clinics to large hospital networks engaged in cutting-edge research. Market growth is catalyzed by advancements in genomic technology, expanding bioinformatics capabilities, and increased understanding of tumor immunology, which fuel optimism for effective treatment options tailored to individual genetic profiles.

KEY MARKET STATISTICS
Base Year [2023] USD 57.14 million
Estimated Year [2024] USD 60.44 million
Forecast Year [2030] USD 81.35 million
CAGR (%) 5.17%

However, the market is not without challenges. The high costs associated with personalized vaccine development and the complexity of neoantigen identification and validation pose significant hurdles. Regulatory challenges, lengthy clinical trial processes, and the need for more robust, large-scale efficacy data further complicate market proliferation. Despite these limitations, opportunities abound, particularly for companies that can innovate in high-throughput sequencing technologies and computational algorithms that enhance neoantigen prediction accuracy. Collaborations between biotech firms and academic institutions to collectively push the boundaries of cancer immunotherapies offer promising pathways for accelerated growth.

Innovation can thrive in areas like improving patient stratification processes, developing better predictive models for vaccine efficacy, and integrating machine learning to shorten development timelines. The market landscape is fluid and competitive, characterized by rapid technological evolution and an increasing number of strategic partnerships. By focusing on personalized therapeutic solutions, companies stand to differentiate themselves significantly. Business growth can be effectively pursued by investing in collaborations that marry cutting-edge technology with real-world clinical applications, streamlining regulatory approval mechanisms, and maximizing insights from early-phase data. This approach not only promises to enhance therapeutic outcomes but also stands to cement a competitive position in this transformative segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neoantigen Cancer Vaccine Market

The Neoantigen Cancer Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of cancer globally
    • Improvements in genomic sequencing and immunotherapy
    • Inclination towards early diagnosis and treatment of cancer
  • Market Restraints
    • High cost and complexity in manufacturing
  • Market Opportunities
    • Ongoing R&D to improve efficacy of neoantigen cancer vaccine
    • Emerging development of combination therapies
  • Market Challenges
    • Adverse effects and ethical issues

Porter's Five Forces: A Strategic Tool for Navigating the Neoantigen Cancer Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neoantigen Cancer Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neoantigen Cancer Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neoantigen Cancer Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neoantigen Cancer Vaccine Market

A detailed market share analysis in the Neoantigen Cancer Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neoantigen Cancer Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neoantigen Cancer Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neoantigen Cancer Vaccine Market

A strategic analysis of the Neoantigen Cancer Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neoantigen Cancer Vaccine Market, highlighting leading vendors and their innovative profiles. These include ", "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc., Advaxis Inc., Agenus Inc., AstraZeneca plc, Avidea Technologies, BioLineRx, BioNTech SE, Brightpath Biotherapeutics Co., Ltd., CureVac N.V., Elicio Therapeutics Inc, F. Hoffmann-La Roche Ltd., Genocea Biosciences Inc, Gilead Sciences, Inc., Gritstone bio, Inc., Immunomic Therapeutics, Inc., IMV Inc, ISA Pharmaceuticals BV, Medigene AG, Merck & Co., Inc., Neophore Limited, Nouscom, Nykode Therapeutics ASA, OSE Immunotherapeutics, and Takis srl.

Market Segmentation & Coverage

This research report categorizes the Neoantigen Cancer Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Off-The Shell Neoantigen Vaccine and Personalized Neo-Antigen Vaccine.
  • Based on Technology, market is studied across HLA Typing, RNA Sequencing, and Whole Genome Sequencing.
  • Based on Delivery Mechanism, market is studied across Electroporation, Gene Gun, Liposomes, and Virosomes.
  • Based on Neoantigen Type, market is studied across Dendritic Cell, Nucleic Acid, Synthetic Long Peptide, and Tumor Cell.
  • Based on Route of Administration, market is studied across Intramuscular, Intravenous, and Transdermal.
  • Based on Application, market is studied across Brain Cancer, Gastrointestinal Cancer, Lung Cancer, and Melanoma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of cancer globally
      • 5.1.1.2. Improvements in genomic sequencing and immunotherapy
      • 5.1.1.3. Inclination towards early diagnosis and treatment of cancer
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and complexity in manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to improve efficacy of neoantigen cancer vaccine
      • 5.1.3.2. Emerging development of combination therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects and ethical issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neoantigen Cancer Vaccine Market, by Product

  • 6.1. Introduction
  • 6.2. Off-The Shell Neoantigen Vaccine
  • 6.3. Personalized Neo-Antigen Vaccine

7. Neoantigen Cancer Vaccine Market, by Technology

  • 7.1. Introduction
  • 7.2. HLA Typing
  • 7.3. RNA Sequencing
  • 7.4. Whole Genome Sequencing

8. Neoantigen Cancer Vaccine Market, by Delivery Mechanism

  • 8.1. Introduction
  • 8.2. Electroporation
  • 8.3. Gene Gun
  • 8.4. Liposomes
  • 8.5. Virosomes

9. Neoantigen Cancer Vaccine Market, by Neoantigen Type

  • 9.1. Introduction
  • 9.2. Dendritic Cell
  • 9.3. Nucleic Acid
  • 9.4. Synthetic Long Peptide
  • 9.5. Tumor Cell

10. Neoantigen Cancer Vaccine Market, by Route of Administration

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Transdermal

11. Neoantigen Cancer Vaccine Market, by Application

  • 11.1. Introduction
  • 11.2. Brain Cancer
  • 11.3. Gastrointestinal Cancer
  • 11.4. Lung Cancer
  • 11.5. Melanoma

12. Americas Neoantigen Cancer Vaccine Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Neoantigen Cancer Vaccine Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Neoantigen Cancer Vaccine Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. "
  • 2. "Geneos Therapeutics, Inc. by Inovio Pharmaceuticals, Inc.
  • 3. Advaxis Inc.
  • 4. Agenus Inc.
  • 5. AstraZeneca plc
  • 6. Avidea Technologies
  • 7. BioLineRx
  • 8. BioNTech SE
  • 9. Brightpath Biotherapeutics Co., Ltd.
  • 10. CureVac N.V.
  • 11. Elicio Therapeutics Inc
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Genocea Biosciences Inc
  • 14. Gilead Sciences, Inc.
  • 15. Gritstone bio, Inc.
  • 16. Immunomic Therapeutics, Inc.
  • 17. IMV Inc
  • 18. ISA Pharmaceuticals BV
  • 19. Medigene AG
  • 20. Merck & Co., Inc.
  • 21. Neophore Limited
  • 22. Nouscom
  • 23. Nykode Therapeutics ASA
  • 24. OSE Immunotherapeutics
  • 25. Takis srl

LIST OF FIGURES

  • FIGURE 1. NEOANTIGEN CANCER VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. NEOANTIGEN CANCER VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEOANTIGEN CANCER VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEOANTIGEN CANCER VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY OFF-THE SHELL NEOANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PERSONALIZED NEO-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY HLA TYPING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GENE GUN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY VIROSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NUCLEIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY SYNTHETIC LONG PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TUMOR CELL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY GASTROINTESTINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY DELIVERY MECHANISM, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY NEOANTIGEN TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM NEOANTIGEN CANCER VACCINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. NEOANTIGEN CANCER VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 284. NEOANTIGEN CANCER VACCINE MARKET, FPNV POSITIONING MATRIX, 2023